Group 1: Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system and a professional data analysis team to optimize inventory turnover efficiency, maintaining a healthy inventory cycle of 1.5-2 months [1] - The overall inventory level has significantly decreased compared to the same period last year, indicating effective inventory control and optimization across channels [1] Group 2: Growth Potential of Secondary and Tertiary Products - The growth trend for secondary and tertiary products is positive, with specific products like the Hejia Dingchuan capsule expected to maintain last year's growth rate, although growth may slow as volume increases [1] - The Xuanyunning series has surpassed 100 million yuan in sales in 2021, aiming for double-digit growth this year, while other products like Shuyanquing spray and Fufang Ganmaoling granules are also expected to maintain high growth rates [1] Group 3: Biopharmaceutical Development - Biopharmaceuticals are a key component of the company's dual strategy, facing a challenging market with high investment and long R&D cycles [2] - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal injection, which is nearing completion of Phase I clinical trials [2] Group 4: Dividend Policy - The company is committed to providing stable returns to investors, maintaining a consistent cash dividend policy since its listing [2] - For 2024, the company plans to distribute a cash dividend of 2.06 billion yuan, with a proposal of 3.5 yuan per 10 shares, while also outlining a mid-year cash dividend plan for 2025 [2]

Core Viewpoint - The company has shown growth in revenue and profit for the fiscal year 2024, but faces challenges in its biopharmaceutical segment due to a competitive environment and high R&D costs [2][3]. Financial Performance - In 2024, the company achieved total revenue of 2.19 billion yuan, a 1.03% increase from 2.17 billion yuan in the previous year [2]. - Profit before tax reached 643.94 million yuan, up 24.24% from 518.28 million yuan year-on-year [2]. - Net profit attributable to shareholders was 521.53 million yuan, reflecting a 23.79% increase from 421.30 million yuan [2]. - In Q1 2025, the company reported a net profit of 97.67 million yuan, an 11.61% increase from 87.52 million yuan in the same period last year [2]. Biopharmaceutical Segment - The biopharmaceutical sector is a key part of the company's strategy but is currently facing a cooling market with high competition and investment risks [2][3]. - The company is optimizing its R&D pipeline, focusing on projects with promising clinical data, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [3]. Inventory and Sales Management - The company has improved its inventory management through a BI intelligent analysis system, achieving a healthier inventory cycle of 1.5 to 2 months [5]. - The company has implemented diverse promotional activities to stimulate end-market consumption and optimize inventory structure [5]. Product Development - The company is optimistic about the growth potential of its second and third-tier products, with specific products like the Guaifenesin capsule and the dizziness relief series expected to maintain or achieve significant growth [6]. Dividend Policy - The company has a consistent cash dividend policy, proposing a cash dividend of 0.35 yuan per share for 2024, totaling 206 million yuan [8]. - The company aims to maintain stable operating cash flow to support its dividend policy unless special funding needs arise [7]. Sales Expense Management - The company has been strict in controlling sales expenses, focusing on second and third-tier products while maintaining a balanced sales expense ratio [9].